Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nurulimab
- Development stage
- Phase 3
- Lead developer
- Biocad
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor expressed on T cells. By inhibiting CTLA-4, nurulimab enhances the activation and proliferation of T lymphocytes, thereby promoting anti-tumor immune responses. It is being developed primarily for the treatment of cancer, with clinical trials conducted in patients with unresectable or metastatic melanoma. Nurulimab has demonstrated a tolerable safety profile and preliminary anti-tumor activity in early-phase clinical studies. The drug was originally developed by Biocad[1][2][3][4][5].
- Other names
- Anti-CTLA4 MAB - BiocadAnti-CTLA-4 MAB - BiocadAnti-CTLA 4 MAB - Biocad
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on nurulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nurulimab.